<DOC>
	<DOCNO>NCT01818921</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics certain dos beloranib obese subject Prader-Willi Syndrome .</brief_summary>
	<brief_title>An Efficacy , Safety , Pharmacokinetics Study Beloranib Obese Subjects With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Confirmed diagnosis PraderWilli Syndrome due chromosome 15 microdeletion , maternal uniparental disomy , imprint defect BMI â‰¥25 kg/m2 Type 2 diabetes mellitus allow Subject must agree stay group home supervision group home site staff ( i.e . home visit ) duration study Stable body weight past 3 month , except home visit Use weight loss agent past 3 month Type 1 diabetes mellitus Current anticipate chronic use narcotic opiate</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Beloranib</keyword>
	<keyword>ZGN-440</keyword>
	<keyword>ZGN-440 injectable suspension</keyword>
	<keyword>ZGN-433</keyword>
</DOC>